Skip to content

Endocrine · Reference monograph

Calcium-regulating thyroid hormone with now-restricted clinical use

Reference compound — not available from Purity Peptides. Shown for research context.

Overview

Calcitonin is a 32-amino-acid peptide hormone secreted by the parafollicular C-cells of the thyroid gland in mammals and by the ultimobranchial bodies in fish and birds. It was discovered in 1962 by Harold Copp, who identified a factor that lowered blood calcium, and is encoded by the CALCA gene, which through alternative splicing also produces calcitonin gene-related peptide (CGRP).

Salmon calcitonin is considerably more potent in mammals than the human hormone, owing to higher receptor affinity and slower dissociation, and it became the basis for most pharmaceutical products. Calcitonin is an approved prescription medicine in the US and EU, but its use was restricted after a 2012 European review associated long-term use with a small increase in malignancy risk; authorised uses in Europe now focus on Paget's disease of bone, hypercalcaemia of malignancy and acute bone loss from sudden immobilisation. In research, calcitonin is a classic tool for osteoclast biology, calcium homeostasis and class B receptor pharmacology, and serum calcitonin is an important tumour marker in medullary thyroid carcinoma research.

Mechanism studied

  1. Calcitonin
  2. Osteoclast receptor
  3. Bone resorption ↓
  4. Serum calcium ↓

Calcitonin binds the calcitonin receptor, a class B G protein-coupled receptor highly expressed on osteoclasts and also present in kidney and brain. Receptor activation couples to Gs, raising cAMP, and to Gq, activating phospholipase C. In osteoclasts this causes rapid cytoplasmic retraction, loss of the ruffled border and reduced secretion of acid and proteolytic enzymes, sharply decreasing bone resorption and calcium release. In the kidney, calcitonin increases calcium and phosphate excretion. When the calcitonin receptor associates with RAMP proteins, it forms amylin receptors, linking calcitonin and amylin pharmacology. Analgesic effects reported in bone pain models may involve central serotonergic and opioid pathways.

Research highlights

  • 01Discovered by Harold Copp in 1962; the term thyrocalcitonin reflected identification of its thyroid source.
  • 02Salmon calcitonin's greater potency in mammals made it the reference molecule for pharmaceutical development.
  • 03A 2012 European Medicines Agency review restricted long-term use after analysis of malignancy data.
  • 04Alternative splicing of CALCA to produce calcitonin or CGRP is a textbook example of tissue-specific RNA processing.
  • 05Open questions include the physiological importance of calcitonin in adult humans, since thyroidectomy does not markedly alter calcium balance.

Latest published research

29,979 papers on PubMed →

  1. Targeting the microbiome in pediatric migraine: gastrointestinal manifestations and the therapeutic role of Bifidobacterium longum

    Fan PC et al. · Gut microbes · 2026 Dec 31 · PMID 41454664

  2. Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?

    Muskiet MHA et al. · Lancet (London, England) · 2026 Dec 20 · PMID 41207308

  3. Mechanisms of neuroimmune crosstalk in vestibular disorders: Linking inflammation with neural circuit dysfunction (Review)

    Pan X et al. · International journal of molecular medicine · 2026 Dec · PMID 42852636

  4. Site-specific transdermal delivery of Qingteng Waifu San in a rheumatoid arthritis rabbit model

    Gao Y et al. · Pakistan journal of pharmaceutical sciences · 2026 Dec 1 · PMID 42708780

  5. A multi-model genome-wide association study identifies genetic variants underlying resistance to Largemouth Bass Ranavirus (LMBV) in Micropterus salmoides

    Xu Y et al. · Comparative biochemistry and physiology. Part D, Genomics & proteomics · 2026 Dec · PMID 42372408

  6. Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis

    Dong Y et al. · Journal of medical economics · 2026 Dec · PMID 41725292

  7. Current research hotspots and difficulties of chronic prostatitis/chronic pelvic pain syndrome: neuroendocrine mechanism

    Shao B et al. · Annals of medicine · 2026 Dec · PMID 41555741

  8. Editors' Note: Calcitonin Gene-Related Peptide Inhibitors and Cardiovascular Risk in People With Migraine

    Ganesh A et al. · Neurology · 2026 Nov 24 · PMID 42950195

Live feed from PubMed (NCBI) for “Calcitonin”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.

Registered studies

154 on ClinicalTrials.gov →

From the public ClinicalTrials.gov registry for “Calcitonin”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.

Key references

  1. [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
  2. [2]PubMed — reviews on calcitonin and bone metabolism

FAQ

  • Salmon calcitonin binds the mammalian calcitonin receptor with higher affinity and dissociates more slowly than human calcitonin, producing a more potent and sustained response. Its stability and potency made it the standard molecule for pharmaceutical products and much experimental research.

  • Both are encoded by the CALCA gene. In thyroid C-cells, RNA processing favours calcitonin, while in neurons alternative splicing produces calcitonin gene-related peptide. The two peptides act on related receptors, with CGRP signalling depending on RAMP1 partnering with the calcitonin receptor-like receptor.

  • In 2012 the European Medicines Agency reviewed data from controlled studies and concluded that long-term use was associated with a slightly increased risk of malignancy. Authorised use was limited to short-term indications, and certain long-term osteoporosis uses were withdrawn.

FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.

Related compounds

WhatsApp